☰

Shawn E. Lupold, Ph.D. - Publications

Affiliations: 
2001 Johns Hopkins University, Baltimore, MD 
Area:
Pharmacology, Molecular Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

68/81 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Graham MK, Wang R, Chikarmane R, Wodu B, Vaghasia A, Gupta A, Zheng Q, Hicks J, Sysa-Shah P, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Zhang Y, ... ... Lupold SE, et al. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 37905029 DOI: 10.1101/2023.09.07.553268  0.427
2023 Lupold SE, Isaacs WB, Luo J. Aggravated Androgen Receptor Activity in Otherwise Indolent Prostate Cancer. European Urology. PMID 37635043 DOI: 10.1016/j.eururo.2023.08.006  0.545
2021 Kurozumi A, Lupold SE. Alternative polyadenylation: An untapped source for prostate cancer biomarkers and therapeutic targets? Asian Journal of Urology. 8: 407-415. PMID 34765448 DOI: 10.1016/j.ajur.2021.05.014  0.415
2021 Mishra A, Zennami K, Velarde E, Thorek DLJ, Yegnasubramanian S, DeWeese TL, Lupold SE. Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods. The Prostate. PMID 34032307 DOI: 10.1002/pros.24171  0.337
2020 Huang CT, Guo X, Bařinka C, Lupold SE, Pomper MG, Gabrielson K, Raman V, Artemov D, Hapuarachchige S. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Molecular Pharmaceutics. PMID 32803984 DOI: 10.1021/Acs.Molpharmaceut.0C00457  0.474
2019 Hapuarachchige S, Huang CT, Donnelly MC, Bařinka C, Lupold SE, Pomper MG, Artemov D. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Molecular Pharmaceutics. PMID 31840521 DOI: 10.1021/Acs.Molpharmaceut.9B00788  0.387
2019 Kurozumi A, Lupold SE. New functions assigned to a microRNA with genetic links to prostate cancer risk. Annals of Translational Medicine. 7: S193. PMID 31656772 DOI: 10.21037/Atm.2019.07.29  0.476
2019 Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, ... ... Lupold SE, et al. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene. PMID 31043708 DOI: 10.1038/S41388-019-0823-5  0.416
2019 Zennami K, Rafiqi F, Liao R, Sealover K, Simons B, Sumitomo M, Shiroki R, Lupold S. Abstract 4501: Loss of miR-21 delays myc-driven prostate cancer progression in the hi-myc transgenic mouse model Cancer Research. 79: 4501-4501. DOI: 10.1158/1538-7445.Sabcs18-4501  0.455
2019 Imada EL, Sanchez DF, Matam T, Collado-Torres L, Wilks C, Dinalankara W, Stupnikov A, Langmead B, Lupold SE, Marchionni L. Abstract 908: Comprehensive analysis of alternative polyadenylation across cancer phenotypes Cancer Research. 79: 908-908. DOI: 10.1158/1538-7445.Am2019-908  0.377
2019 Zennami* K, Rafiqi F, Liao R, Sealover K, Simons B, Sumitomo M, Shiroki R, Lupold S. PD05-10 LOSS OF MIR-21 DELAYS MYC-DRIVEN PROSTATE CANCER PROGRESSION IN THE HI-MYC TRANSGENIC MOUSE MODEL Journal of Urology. 201. DOI: 10.1097/01.JU.0000555070.63543.0b  0.346
2019 Zennami K, Rafiqi F, Liao R, Sealover K, Simons B, Sumitomo M, Shiroki R, Lupold S. Loss of miR-21 delays Myc-driven prostate cancer progression in the Hi-Myc transgenic mouse model European Urology Supplements. 18: e62-e63. DOI: 10.1016/S1569-9056(19)30047-8  0.391
2019 Mishra A, Zennami K, Velarde E, Coulter JB, Yegnasubramanian S, Lupold S, DeWeese TL. Circulating Tumor DNA Is an Accurate Measurement of Determining Radiation-Induced Therapeutic Response and Tumor Burden Monitoring in a Prostate Cancer Bone Metastases Murine Model International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1065  0.434
2018 Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA. Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical Chemistry. PMID 30518666 DOI: 10.1373/Clinchem.2018.293365  0.592
2018 Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, Rafiqi FH, Kurozumi A, Hatano K, Lupold SE. PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance. Molecular Cancer Research : McR. PMID 30518628 DOI: 10.1158/1541-7786.Mcr-18-0837  0.502
2018 Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Scientific Reports. 8: 7189. PMID 29739972 DOI: 10.1038/S41598-018-25320-Z  0.417
2018 Lupold SE. Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey. American Journal of Clinical and Experimental Urology. 6: 78-86. PMID 29666835  0.388
2018 Zennami K, Rafiqi F, Liao R, Sealover K, Simons B, Lupold S. MP29-07 LOSS OF MIR-21 DELAYS MYC-DRIVEN PROSTATE CANCER PROGRESSION IN THE HI-MYC TRANSGENIC MOUSE MODEL Journal of Urology. 199. DOI: 10.1016/S1569-9056(19)30047-8  0.509
2018 Lupold SE, Pienta KJ, Koul HK, Chung LW, Sun Y. Obituary for Donald S. Coffey: Remembering a pioneer in the field of prostate cancer research. (1932–2017) Asian Journal of Urology. 5: 1-2. DOI: 10.1016/J.Ajur.2017.11.006  0.446
2017 Martino T, Kudrolli TA, Kumar B, Salviano I, Mencalha A, Coelho MGP, Justo G, Costa PRR, Sabino KCC, Lupold SE. The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. The Prostate. PMID 29105806 DOI: 10.1002/Pros.23455  0.489
2017 Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold SE, Pienta KJ, Pomper MG. Low level endogenous prostate-specific membrane antigen (PSMA) expression in non-prostatic tumor xenografts is sufficient for in vivo tumor targeting and imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29025989 DOI: 10.2967/Jnumed.117.191221  0.515
2017 Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE. Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens. Bmc Cancer. 17: 32. PMID 28061773 DOI: 10.1186/S12885-016-3008-4  0.529
2017 Zennami K, Hatano K, Liao R, Rafiqi F, Choi SM, Lupold S. MP99-14 PDCD4 IS A CHECK POINT OF MIR-21 INDUCED CASTRATION RESISTANCE IN HUMAN PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3100  0.476
2017 Zennami K, Zhang Y, Zhou H, Thorek D, DeWeese T, Lupold S. MP83-12 TISSUE-SPECIFIC RADIATION SENSITIZATION OF PROSTATE CANCER BY APTAMER TARGETED SIRNA KNOCK-DOWN OF DNA REPAIR PATHWAY Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2580  0.47
2016 Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, Yeater DB, Ewing CM, Luo J, Isaacs WB, Marchionni L, Lupold SE. Identification of miR-30b-3p and miR-30d-5p as direct regulators of Androgen Receptor Signaling in Prostate Cancer by complementary functional microRNA library screening. Oncotarget. PMID 27683042 DOI: 10.18632/Oncotarget.12241  0.575
2016 Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE. Development and application of a novel model system to study 'active' and 'passive' tumor targeting. Molecular Cancer Therapeutics. PMID 27486224 DOI: 10.1158/1535-7163.Mct-16-0051  0.531
2016 Kumar B, Lupold SE. MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. Asian Journal of Andrology. PMID 27056344 DOI: 10.4103/1008-682X.177839  0.449
2015 Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA. Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. The Prostate. PMID 26499105 DOI: 10.1002/Pros.23115  0.464
2015 Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWEese TL, Lupold SE. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts. Molecular Cancer Therapeutics. PMID 26438155 DOI: 10.1158/1535-7163.Mct-15-0291-T  0.458
2015 Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Research. 43: 4075-86. PMID 25845598 DOI: 10.1093/Nar/Gkv273  0.389
2015 Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 771-80. PMID 25501577 DOI: 10.1158/1078-0432.Ccr-14-0891  0.481
2014 Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. The Prostate. 74: 1655-62. PMID 25252191 DOI: 10.1002/Pros.22883  0.584
2014 Wu P, Sokoll LJ, Kudrolli TA, Chowdhury WH, Ma R, Liu MM, Rodriguez R, Lupold SE. A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector. The Prostate. 74: 1286-96. PMID 25065656 DOI: 10.1002/Pros.22845  0.305
2014 Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG. Evaluation of prostate-specific membrane antigen as an imaging reporter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 805-11. PMID 24700883 DOI: 10.2967/Jnumed.113.134031  0.385
2014 Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of Cellular Biochemistry. 115: 1505-15. PMID 24604720 DOI: 10.1002/Jcb.24805  0.486
2014 Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. Chemmedchem. 9: 1356-60. PMID 24591351 DOI: 10.1002/Cmdc.201300549  0.403
2014 Hatano K, Kumar B, Mears B, Chowdhury WH, Rodriguez R, Zhang Y, DeWeese TL, Lupold SE. MP24-12 FUNCTIONAL SCREENING IDENTIFIES MICRORNAS WHICH ALTER PROSTATE CANCER SENSITIVITY TO RADIATION THERAPY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.293  0.474
2014 Hedayati M, Hatano K, Kumar B, Chowdhury W, Rodriguez R, Zhang Y, DeWeese T, Lupold S. Functional Screening Identifies MicroRNAs That Alter Prostate Cancer Sensitivity to Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 90: S88-S89. DOI: 10.1016/J.Ijrobp.2014.05.482  0.472
2013 Johnson TJ, Höti N, Liu C, Chowdhury WH, Li Y, Zhang Y, Lupold SE, Deweese T, Rodriguez R. Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer. Cancer Gene Therapy. 20: 394-402. PMID 23764901 DOI: 10.1038/Cgt.2013.34  0.474
2013 Raval R, Ni X, Zhang Y, Zhou H, Meeker A, Lupold S, DeWeese T. Systemic Delivery of Synthesized Aptamer-siRNA Chimeras Results in Prostate-Targeted Radiosensitization International Journal of Radiation Oncology*Biology*Physics. 87: S139. DOI: 10.1016/J.Ijrobp.2013.06.358  0.559
2013 Ribas J, Lupold SE. The role of miR-21, an androgen-regulated MicroRNA, in prostate cancer Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications. 2147483647: 285-305. DOI: 10.1007/978-1-4614-6182-1_18  0.402
2012 Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. Journal of Biomedicine & Biotechnology. 2012: 180363. PMID 23093837 DOI: 10.1155/2012/180363  0.489
2012 Lupold SE, Johnson T, Chowdhury WH, Rodriguez R. A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer. Plos One. 7: e36535. PMID 22590558 DOI: 10.1371/Journal.Pone.0036535  0.311
2012 Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, Rodriguez R, Mendell JT, Lupold SE. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Research. 40: 6821-33. PMID 22505577 DOI: 10.1093/Nar/Gks308  0.34
2012 Wu P, Oh D, Chowdhury WH, Kudrolli TA, Liu MM, Sokoll L, Rodriguez R, Lupold SE. Abstract 2392: A novel approach for detecting viable and tissue-specific circulating tumor cells Cancer Research. 72: 2392-2392. DOI: 10.1158/1538-7445.Am2012-2392  0.461
2011 Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angewandte Chemie (International Ed. in English). 50: 9167-70. PMID 21861274 DOI: 10.1002/Anie.201102872  0.459
2011 Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. The Journal of Clinical Investigation. 121: 2383-90. PMID 21555850 DOI: 10.1172/Jci45109  0.504
2011 Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, Netto G, Carducci M, Lupold SE, Rodriguez R. Does valproic acid induce neuroendocrine differentiation in prostate cancer? Journal of Biomedicine & Biotechnology. 2011: 607480. PMID 20981253 DOI: 10.1155/2011/607480  0.461
2011 Ni X, Zhang Y, Ribas J, Chodhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Abstract 5387: Prostate-targeted radiosensitization via aptamer-shRNA chimeras Cancer Research. 71: 5387-5387. DOI: 10.1158/1538-7445.Am2011-5387  0.509
2011 Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. 403 GROWTH INHIBITION OF PROSTATE CANCER XENOGRAFTS UPON CHRONIC TREATMENT WITH VALPROIC ACID BY CELL CYCLE ARREST AND INHIBITION OF TUMOR VASCULATURE Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.492  0.427
2010 Wu P, Kudrolli TA, Chowdhury WH, Liu MM, Rodriguez R, Lupold SE. Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening. Cancer Research. 70: 9549-53. PMID 20670952 DOI: 10.1158/0008-5472.Can-10-1760  0.347
2010 Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R. Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses Cancer Gene Therapy. 17: 585-597. PMID 20448671 DOI: 10.1038/Cgt.2010.15  0.455
2010 Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE, Deweese TL, Rodriguez R. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. International Journal of Radiation Biology. 86: 220-9. PMID 20201650 DOI: 10.3109/09553000903419338  0.357
2010 Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (Georgetown, Tex.). 9: 923-9. PMID 20160498 DOI: 10.4161/Cc.9.5.10930  0.453
2010 Hoti NU, Mustafa S, Chowdhury W, Johnson T, Lupold SE, Rodriguez R. Abstract 1510: Improving replication kinetics by using a single shRNA p21/Waf-1 construct in backbone of prostate specific CRAd Cancer Research. 70: 1510-1510. DOI: 10.1158/1538-7445.Am10-1510  0.504
2010 Ni X, Zhang Y, Ribas J, DeWeese TL, Lupold SE. Abstract 1503: PSMA Aptamer-targeted siRNAs selectively Eehance prostate cancer radiation sensitivity Cancer Research. 70: 1503-1503. DOI: 10.1158/1538-7445.Am10-1503  0.535
2010 DeWeese T, Ni X, Zhang Y, Hedayati M, Lupold S. Substantial Increases in Prostate Cancer Tumor Control Result from a Combination of PSMA Aptamer-targeted siRNAs and Radiation International Journal of Radiation Oncology*Biology*Physics. 78: S113-S114. DOI: 10.1016/J.Ijrobp.2010.07.290  0.509
2009 Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Research. 69: 7165-9. PMID 19738047 DOI: 10.1158/0008-5472.Can-09-1448  0.455
2009 DeWeese T, Ni X, Zhang Y, Lupold S. PSMA Aptamer-targeted SiRNAs Selectively Enhance Prostate Cancer Radiation Sensitivity International Journal of Radiation Oncology*Biology*Physics. 75: S91-S92. DOI: 10.1016/J.Ijrobp.2009.07.225  0.498
2008 Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry. 51: 7933-43. PMID 19053825 DOI: 10.1021/Jm801055H  0.415
2008 Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) Journal of Medicinal Chemistry. 51: 4504-4517. PMID 18637669 DOI: 10.1021/Jm800111U  0.397
2007 Höti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1495-503. PMID 17565351 DOI: 10.1038/Sj.Mt.6300223  0.482
2006 Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 768-78. PMID 16990052 DOI: 10.1016/J.Ymthe.2006.07.009  0.367
2006 Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 319: 533-42. PMID 16868035 DOI: 10.1124/Jpet.106.106658  0.447
2005 Lupold SE, Rodriguez R. Adenoviral gene therapy, radiation, and prostate cancer. Reviews in Urology. 7: 193-202. PMID 16985830  0.374
2004 Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Molecular Cancer Therapeutics. 3: 597-603. PMID 15141017  0.343
2004 Lupold SE, Rodriguez R. 275. Prostate Targeting Peptides Via the Prostate Specific Membrane Antigen Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.212  0.456
2002 Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 62: 4029-33. PMID 12124337  0.595
Low-probability matches (unlikely to be authored by this person)
2011 Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: Clinical applications and promising new horizons Current Medicinal Chemistry. 18: 4206-4214. PMID 21838685 DOI: 10.2174/092986711797189600  0.288
1996 Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proceedings of the National Academy of Sciences of the United States of America. 93: 2442-7. PMID 8637893 DOI: 10.1073/Pnas.93.6.2442  0.277
1996 Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes & Development. 10: 1219-32. PMID 8675009 DOI: 10.1101/Gad.10.10.1219  0.264
2004 Lupold SE, Chowdhury WH, Rodriguez R. 137. pFex: a novel fiber exchange system for the creation of modified-fiber gene therapy vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.093  0.261
2004 Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M, Forrester KS, Harris CC. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Research. 64: 2350-6. PMID 15059885 DOI: 10.1158/0008-5472.Can-2287-2  0.26
2007 DeWeese T, Collis S, Lupold S, Chowdury W, Kudrolli T, Swartz M, Rodriguez R. Optimization of siRNA-Transgene Expression in Adenoviral Vector Systems for Radiation Sensitizing Strategies International Journal of Radiation Oncology*Biology*Physics. 69: S595-S596. DOI: 10.1016/J.Ijrobp.2007.07.1896  0.25
2006 Lupold SE, Kudrolli TA, Chowdhurry WH, Rodriguez R. 142. pFex: A Highly Efficient Adenoviral Vector System for Fiber Gene Modification Molecular Therapy. 13: S56. DOI: 10.1016/J.Ymthe.2006.08.163  0.245
2007 Lupold SE, Kudrolli TA, Chowdhury WH, Wu P, Rodriguez R. A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Research. 35: e138. PMID 17965092 DOI: 10.1093/Nar/Gkm914  0.236
2014 Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE. Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor. Nanomedicine (London, England). 9: 2729-43. PMID 24547783 DOI: 10.2217/Nnm.13.207  0.208
1995 Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, Harris CC. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 10: 2103-11. PMID 7784055  0.142
1991 Kenten JH, Casadei J, Link J, Lupold S, Willey J, Powell M, Rees A, Massey R. Rapid electrochemiluminescence assays of polymerase chain reaction products Clinical Chemistry. 37: 1626-1632. DOI: 10.1093/clinchem/37.9.1626  0.092
2009 Byun Y, Mease RC, Lupold SE, Pomper MG. Recent Development of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII) Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. 881-910. DOI: 10.1002/9780470508169.ch36  0.09
1995 Newton K, Winberg B, Yamato K, Lupold S, Stern D. Evidence for a novel mitochondrial promoter preceding the cox2 gene of perennial teosintes. The Embo Journal. 14: 585-593. DOI: 10.1002/j.1460-2075.1995.tb07034.x  0.056
Hide low-probability matches.